Q-omics provides the consensus-scored GATAD1 profile across patient tissues and cancer cell-line models. GATAD1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, GATAD1 is differentially expressed in 13, with the highest sampling consensus in HNSC. Additionally, GATAD1 RNA expression shows 20,508 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight BRCA, HNSC, and UVM as cancer lineages where GATAD1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GATAD1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GATAD1 survival associations across molecular data types. GATAD1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GATAD1 RNA expression–survival associations across cancer types. High GATAD1 expression shows unfavorable associations in UVM, LGG, CESC and KICH, but favorable associations in BRCA and SKCM. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify BRCA as the clearest survival context for GATAD1 RNA expression.
This table summarizes GATAD1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 2. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for GATAD1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GATAD1 shows lower tumor expression in THCA and higher tumor expression in HNSC, KIRC, LIHC, KIRP and BLCA. The HNSC box plot shows higher GATAD1 RNA expression in tumor versus normal tissue (log2 FC = +1.058, t-test p < 0.001).
This table shows molecular features associated with GATAD1 in patient tissues and cancer cell lines. In patient samples, GATAD1 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, GATAD1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in URINARY_TRACT, while CRISPR and shRNA rows add functional-dependency signals in UPPER_AERODIGESTIVE_TRACT and BONE.
